SEC filings and other documents

Q2 2026 sales up 11.5% with margin pressure, capacity expansion, and strong U.S. growth.

Strong growth, market share gains, and financial recovery position First Defense® for expansion.

Record sales and margin growth position First Defense® for continued market share gains.

All proposals passed and a major manufacturing expansion was announced to support growth.

Record revenue, margin gains, and market share growth highlight strong Q1 2026 performance.

First Defense® gains share in a growing market, fueling record sales and margin expansion.

Double-digit growth, rising market share, and financial recovery fuel expansion in scours prevention.

Sales grew 4.3% to $27.6M in 2025, with gross margin up to 41% and net loss reduced to $1M.

Shift to First Defense drives growth as Re-Tain is paused; Q4 sales near record highs.

Net income swung to $1.8M and gross margin hit 43% as operational improvements drove growth.

First Defense® sales grow as Re-Tain® nears FDA approval, driving margin and market expansion.

Strong growth, expanded capacity, and late-stage FDA review for new product mark a pivotal year.

Sales and margins surged in Q2 2025, but H2 may soften as inventory effects fade.

Non-antibiotic animal health products drive sales growth and market expansion.

Sales and margins rebound as expanded capacity meets demand; Re-Tain field trials begin in 2025.

Q1 2025 saw higher sales, improved margins, and progress on Re-Tain® FDA approval.